{"id":"clinical-treatment","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL7257","moleculeType":"Small molecule","molecularWeight":"218.30"},"_dailymed":{"setId":"7d66d80c-f389-249b-e053-2991aa0a8d0b","title":"SECRET CLINICAL STRENGTH NIGHT TREATMENT SOFT SOOTHING LAVENDER (ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY) CREAM [THE PROCTER & GAMBLE MANUFACTURING COMPANY]"},"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Clinical treatment is a patient-centered approach that takes into account the individual's medical history, lifestyle, and preferences to develop a personalized treatment plan. This approach often involves a multidisciplinary team of healthcare professionals working together to provide comprehensive care. By focusing on prevention, early detection, and timely intervention, clinical treatment aims to improve patient outcomes and quality of life.","oneSentence":"Clinical treatment involves the application of evidence-based medical practices to manage and treat various health conditions.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:03.336Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Management of various health conditions"}]},"trialDetails":[{"nctId":"NCT05622136","phase":"PHASE2","title":"Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2023-09-10","conditions":"Liver Cancer, Hepatocellular Carcinoma","enrollment":28},{"nctId":"NCT06868914","phase":"PHASE1","title":"Phase I Trial of High-Density Theta Burst Stimulation (hdTBS)","status":"NOT_YET_RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2026-04-01","conditions":"Healthy Volunteers","enrollment":35},{"nctId":"NCT07042945","phase":"PHASE1","title":"MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-09","conditions":"HIV Infection","enrollment":28},{"nctId":"NCT03654105","phase":"PHASE2","title":"Screening and Multiple Intervention on Lung Epidemics","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2019-07-23","conditions":"Inflammation, Smoking Cessation, Diet Modification","enrollment":2000},{"nctId":"NCT07496073","phase":"PHASE1","title":"A Phase I, Single-arm, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Cell Infusion in Adult Subjects With Recurrent or Progressive Malignant Primary Brain Tumors（CROWN）","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-03-20","conditions":"Brain (Nervous System) Cancers","enrollment":30},{"nctId":"NCT07433556","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy Volunteers","status":"RECRUITING","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2026-03-23","conditions":"Healhty","enrollment":86},{"nctId":"NCT06857929","phase":"NA","title":"\"Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition\"","status":"RECRUITING","sponsor":"IMDEA Food","startDate":"2026-03-01","conditions":"Metabolic Syndrome, Obesity Prevention, Obesity and Overweight","enrollment":106},{"nctId":"NCT06396754","phase":"","title":"Deployment and Clinical Evaluation of an AI-powered Digital Oncology Biomarker Tool to guidE Treatment in TNBC","status":"NOT_YET_RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2026-08-01","conditions":"Triple Negative Breast Cancer","enrollment":50},{"nctId":"NCT04929028","phase":"PHASE2","title":"Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-09","conditions":"AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT07494773","phase":"PHASE1, PHASE2","title":"Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection","status":"NOT_YET_RECRUITING","sponsor":"University of Oklahoma","startDate":"2026-06-01","conditions":"Burns, Wound Infection","enrollment":50},{"nctId":"NCT03907475","phase":"PHASE2","title":"Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-16","conditions":"Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":115},{"nctId":"NCT04704661","phase":"PHASE1","title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-09","conditions":"Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma","enrollment":51},{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT06925737","phase":"PHASE3","title":"A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-13","conditions":"Prostate Cancer, Prostatic Neoplasms","enrollment":1440},{"nctId":"NCT07494877","phase":"","title":"Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2025-09-01","conditions":"Infertility","enrollment":300},{"nctId":"NCT07497256","phase":"NA","title":"Shared Decision-Making Decision Aid for Newly Diagnosed Breast Cancer : A Multi-Center Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Xiamen University","startDate":"2026-04","conditions":"Breast Cancer, Decision Aid, Shared Decision Making","enrollment":160},{"nctId":"NCT05600894","phase":"PHASE2","title":"Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-06-27","conditions":"Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts","enrollment":132},{"nctId":"NCT05687123","phase":"PHASE1","title":"Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-14","conditions":"Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm, Stage III Pancreatic Neuroendocrine Tumor AJCC v8","enrollment":24},{"nctId":"NCT06385483","phase":"PHASE2","title":"Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-28","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":19},{"nctId":"NCT07156227","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-22","conditions":"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma","enrollment":39},{"nctId":"NCT06514261","phase":"PHASE1","title":"Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-12-18","conditions":"Acute Myeloid Leukemia","enrollment":45},{"nctId":"NCT01896999","phase":"PHASE1, PHASE2","title":"Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-03-07","conditions":"Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma","enrollment":146},{"nctId":"NCT03816345","phase":"PHASE1","title":"Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-16","conditions":"Autoimmune Disease, Crohn Disease, Dermatomyositis","enrollment":300},{"nctId":"NCT06439836","phase":"PHASE1","title":"Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-05","conditions":"Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma","enrollment":27},{"nctId":"NCT05053971","phase":"PHASE1, PHASE2","title":"Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-16","conditions":"Advanced Malignant Solid Neoplasm, Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma","enrollment":49},{"nctId":"NCT00007150","phase":"PHASE2","title":"Treatment of Hemochromatosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2001-01-01","conditions":"Hemochromatosis","enrollment":622},{"nctId":"NCT07494305","phase":"PHASE2","title":"Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.","status":"RECRUITING","sponsor":"LB Pharmaceuticals Inc.","startDate":"2026-01-23","conditions":"Bipolar I Disorder","enrollment":320},{"nctId":"NCT04550494","phase":"PHASE2","title":"Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-26","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma","enrollment":36},{"nctId":"NCT04665739","phase":"PHASE2","title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-03","conditions":"Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm","enrollment":70},{"nctId":"NCT06389136","phase":"PHASE3","title":"A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-06-14","conditions":"Atopic Dermatitis","enrollment":200},{"nctId":"NCT06356610","phase":"NA","title":"Pharmacokinetic and Subjective Effects of Heated Tobacco Products","status":"COMPLETED","sponsor":"Altria Client Services LLC","startDate":"2024-02-06","conditions":"Tobacco Use","enrollment":80},{"nctId":"NCT06498635","phase":"PHASE3","title":"Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-04-01","conditions":"Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":306},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT04387656","phase":"","title":"NCI COVID-19 in Cancer Patients, NCCAPS Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-05","conditions":"COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm","enrollment":1877},{"nctId":"NCT07494539","phase":"NA","title":"Induction of Labor by Cervical Ripening and Transcutaneous Electrical Nerve Stimulation (TENS)","status":"NOT_YET_RECRUITING","sponsor":"HOT Noémie","startDate":"2026-04-01","conditions":"Labor Pain, Induction of Labor","enrollment":132},{"nctId":"NCT05112601","phase":"PHASE2","title":"Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-02","conditions":"Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma","enrollment":81},{"nctId":"NCT06562075","phase":"NA","title":"A Post-market-clinical Follow-up Investigation of Safety and Performance by Decoria® Intense Strong","status":"COMPLETED","sponsor":"Bohus Biotech AB","startDate":"2024-09-06","conditions":"Jawline Contour Deficit","enrollment":114},{"nctId":"NCT07061951","phase":"PHASE2","title":"Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-09-08","conditions":"Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia","enrollment":20},{"nctId":"NCT07061964","phase":"PHASE2","title":"Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-11-25","conditions":"Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8","enrollment":111},{"nctId":"NCT04166409","phase":"PHASE3","title":"A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-01-31","conditions":"Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma","enrollment":170},{"nctId":"NCT06203600","phase":"PHASE2, PHASE3","title":"Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-24","conditions":"Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma","enrollment":224},{"nctId":"NCT07200466","phase":"NA","title":"Individualised Endometrial Cancer Risk Stratification by Bayesian Prediction Model (ENDORISK), Optimizing Clinical Implementation","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2025-10-23","conditions":"Endometrial Cancer","enrollment":735},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT04524871","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-01","conditions":"Advanced Liver Cancers","enrollment":518},{"nctId":"NCT07493993","phase":"PHASE2","title":"Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-06-01","conditions":"ESCC","enrollment":26},{"nctId":"NCT03686124","phase":"PHASE1, PHASE2","title":"ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2019-05-14","conditions":"Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult","enrollment":375},{"nctId":"NCT04284787","phase":"PHASE2","title":"BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-16","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":60},{"nctId":"NCT04052555","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-24","conditions":"Bilateral Breast Carcinoma, HER2-Negative Breast Carcinoma, Localized Breast Carcinoma","enrollment":42},{"nctId":"NCT04164082","phase":"PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-03-18","conditions":"Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8","enrollment":161},{"nctId":"NCT07170033","phase":"NA","title":"The Effect of the DASH Diet on Treatment Outcomes in Adults Diagnosed With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Istanbul Health and Technology University","startDate":"2024-05-06","conditions":"Rheumatoid Arthritis","enrollment":49},{"nctId":"NCT07497958","phase":"NA","title":"Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-04-01","conditions":"Renal Cell Carcinoma (RCC), Renal Function Abnormal","enrollment":174},{"nctId":"NCT01468896","phase":"PHASE1, PHASE2","title":"Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-10-26","conditions":"Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma","enrollment":23},{"nctId":"NCT04310020","phase":"PHASE2","title":"Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-13","conditions":"Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8","enrollment":47},{"nctId":"NCT06980038","phase":"PHASE2","title":"Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-21","conditions":"Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma","enrollment":44},{"nctId":"NCT03811015","phase":"PHASE3","title":"Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-16","conditions":"Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":636},{"nctId":"NCT05773274","phase":"PHASE2","title":"Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-12","conditions":"Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2, Unresectable Digestive System Neuroendocrine Tumor G1","enrollment":100},{"nctId":"NCT07495397","phase":"NA","title":"Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targeted Maintenance Therapy After Initial Treatment of Stage III-IV Epithelial Ovarian Cancer (RO/R1)","status":"RECRUITING","sponsor":"The First Hospital of Jilin University","startDate":"2025-11-01","conditions":"Epithelial Ovarian Cancer","enrollment":98},{"nctId":"NCT06126276","phase":"PHASE2","title":"Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-05-07","conditions":"Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm","enrollment":70},{"nctId":"NCT07188818","phase":"NA","title":"Clinical Investigation on Lips Treated With HA-filler","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bohus Biotech AB","startDate":"2024-12-09","conditions":"Aesthetic Correction of the Lips","enrollment":100},{"nctId":"NCT05733585","phase":"","title":"Clinical Study of Patients Treated With PuraBond Haemostatic Agent During Abdominal Aorta Open Repair","status":"RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2023-02-15","conditions":"Hemostatic","enrollment":100},{"nctId":"NCT07496060","phase":"PHASE4","title":"Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas","status":"COMPLETED","sponsor":"Fayoum University","startDate":"2025-08-10","conditions":"Anterior Chamber Granulomatous Uveitis","enrollment":66},{"nctId":"NCT03854474","phase":"PHASE1, PHASE2","title":"Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-11-18","conditions":"Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8","enrollment":30},{"nctId":"NCT06400238","phase":"PHASE2","title":"Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-10-15","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":35},{"nctId":"NCT04585958","phase":"PHASE1","title":"Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-21","conditions":"Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm","enrollment":55},{"nctId":"NCT04090398","phase":"PHASE2","title":"Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-04","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone","enrollment":70},{"nctId":"NCT06965114","phase":"PHASE1, PHASE2","title":"Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-27","conditions":"Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell Leukemia","enrollment":84},{"nctId":"NCT05372640","phase":"PHASE1","title":"Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-10","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma","enrollment":45},{"nctId":"NCT06456346","phase":"PHASE3","title":"Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-16","conditions":"Essential Thrombocythemia","enrollment":300},{"nctId":"NCT05941520","phase":"PHASE2","title":"Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-23","conditions":"Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ","enrollment":80},{"nctId":"NCT06311227","phase":"PHASE2","title":"Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-12-16","conditions":"Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant","enrollment":20},{"nctId":"NCT07147231","phase":"PHASE1, PHASE2","title":"Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461) in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-31","conditions":"Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8","enrollment":86},{"nctId":"NCT06166849","phase":"NA","title":"Clinical Evaluation of an Experimental Remineralization Product","status":"COMPLETED","sponsor":"Ivoclar Vivadent AG","startDate":"2023-03-28","conditions":"White Spot Lesion","enrollment":43},{"nctId":"NCT02496208","phase":"PHASE1","title":"Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-07-22","conditions":"Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma","enrollment":152},{"nctId":"NCT06185985","phase":"PHASE4","title":"Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2024-03-25","conditions":"Attention-Deficit/Hyperactivity Disorder","enrollment":161},{"nctId":"NCT06498648","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-18","conditions":"Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma, Advanced Soft Tissue Sarcoma","enrollment":74},{"nctId":"NCT01089101","phase":"PHASE1, PHASE2","title":"Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-07-07","conditions":"Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Neurofibromatosis Type 1","enrollment":217},{"nctId":"NCT05718375","phase":"PHASE2","title":"Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria","status":"COMPLETED","sponsor":"Curacle Co., Ltd.","startDate":"2023-02-14","conditions":"Diabetic Nephropathies","enrollment":240},{"nctId":"NCT03741023","phase":"NA","title":"Disorders of the Acute Phase Response Following Trauma and Invasive Surgery","status":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","startDate":"2019-12-12","conditions":"Acute Phase Response","enrollment":320},{"nctId":"NCT06982222","phase":"PHASE1","title":"Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-31","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma","enrollment":24},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT05111561","phase":"PHASE1","title":"Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-02","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm","enrollment":42},{"nctId":"NCT05136196","phase":"PHASE2","title":"BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-12-06","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":150},{"nctId":"NCT05490771","phase":"PHASE2","title":"Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-20","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm","enrollment":35},{"nctId":"NCT02834013","phase":"PHASE2","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-30","conditions":"Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma","enrollment":818},{"nctId":"NCT07496008","phase":"","title":"Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population","status":"NOT_YET_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-03-25","conditions":"Isavuconazole, Invasion Pulmonary Mycosis","enrollment":150},{"nctId":"NCT06602414","phase":"","title":"Evaluation of Clinical Results of Patients Treated Conservatively for Distal Biceps Tendon Lesions","status":"COMPLETED","sponsor":"Istituto Ortopedico Rizzoli","startDate":"2024-10-31","conditions":"Tendon Rupture","enrollment":30},{"nctId":"NCT03698019","phase":"PHASE2","title":"A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-02-15","conditions":"Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":313},{"nctId":"NCT03191149","phase":"PHASE2","title":"Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-04-25","conditions":"Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7","enrollment":46},{"nctId":"NCT06169215","phase":"PHASE2","title":"Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-23","conditions":"Multiple Myeloma","enrollment":70},{"nctId":"NCT06869447","phase":"NA","title":"New York Better Breathing Study","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-15","conditions":"Localized Lung Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8","enrollment":100},{"nctId":"NCT04527406","phase":"NA","title":"Early Surgical Intervention of Congenital Hemivertebra in Young Children","status":"WITHDRAWN","sponsor":"Children's Hospital of Fudan University","startDate":"2025-03-01","conditions":"Congenital Hemivertebra","enrollment":""},{"nctId":"NCT07495657","phase":"","title":"Pre-Post Multimodal Assessment Of Severe Psoriasis Vulgaris Using Clinical, Dermoscopic And QoL Measures","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-05-01","conditions":"Psoriasis Vulgaris","enrollment":45},{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT07222488","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-09","conditions":"Bladder Cancer, Urinary Bladder Neoplasms","enrollment":45},{"nctId":"NCT07247110","phase":"PHASE1","title":"A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-16","conditions":"Malignant Neoplasm","enrollment":250},{"nctId":"NCT02595931","phase":"PHASE1","title":"M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-07-22","conditions":"Metastatic Colorectal Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm","enrollment":66},{"nctId":"NCT07189871","phase":"PHASE1, PHASE2","title":"177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Radiopharm Theranostics, Ltd","startDate":"2026-02-23","conditions":"Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer)","enrollment":61},{"nctId":"NCT04840589","phase":"PHASE1","title":"Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-02","conditions":"Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma","enrollment":66},{"nctId":"NCT03375320","phase":"PHASE3","title":"Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-10-26","conditions":"Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm","enrollment":298},{"nctId":"NCT06050252","phase":"PHASE2","title":"Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-10","conditions":"Resectable Intrahepatic Cholangiocarcinoma","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":29185,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Clinical treatment such as fluid infusion"],"phase":"marketed","status":"active","brandName":"Clinical treatment","genericName":"Clinical treatment","companyName":"University of Pernambuco","companyId":"university-of-pernambuco","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clinical treatment involves the application of evidence-based medical practices to manage and treat various health conditions. Used for Management of various health conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}